Being addictive to drugs is a chronic disease that affects both a person’s brain and their behavior resulting in a significant impact on their quality of life. Treatment of opioid use disorder (OUD) is often administered over long periods of time or chronically.
The most common treatments are Medication Assisted Treatments (MAT) based on buprenorphine, methadone or naltrexone. Buprenorphine is often combined with the antagonist naloxone to help prevent misuse by intravenous injection. The most frequently used medication as part of a MAT program in the US is buprenorphine/naloxone which can be taken under the tongue as a tablet or film. Methadone is most commonly administered orally in a supervised setting, while naltrexone is most frequently given as a monthly injection.
Pharmacological treatment should be provided as part of a complete treatment plan and include behavioral therapy.
People where misuse of opioids has turned to illicit drug use face a large risk of suffering life-threatening overdoses where rescue medications such as naloxone are often required.
Zubsolv®: Maintenance treatment for OUD
Zubsolv is indicated for the maintenance treatment of OUD and should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support. The drug is based on Orexo´s sublingual drug delivery platform and is available in six dosage strengths.
Orexo commercializes Zubsolv in the US. In the EU, Zubsolv is commercialized by Orexo´s partner Accord Healthcare. Rights to other markets are owned by Orexo.
MODIA®: Digital mental health program for OUD
MODIA is a 6-month digital mental health program designed to help patients with OUD develop behavioral coping skills. MODIA incorporates various supportive techniques like cognitive behavioral therapy (CBT) and motivational interviewing. MODIA is intended for use by patients who are engaged in a clinician-directed Medication-Assisted Treatment (MAT) plan for OUD.
Products under development: Overdose rescue medications
OX124 is a late-stage, high dose nasal powder with naloxone to be used in life-threatening situations where the overdose on any opioid is suspected, indicated by e.g. unconsciousness or opioid-induce respiratory depression (OIRD).
OX125 is an early-stage powder-based formulation of nalmefene for intranasal administration in life-threatening situations where the overdose on any opioid is suspected. Nalmefene has a prolonged half-life compared to naloxone and may potentially last longer than the majority of highly potent synthetic opioids.
Orexo's Zubsolv has the potential to help
6.1* million
people in the US towards an OUD free life
*Number of people suffering from opioid dependence in the US in 2023
You are now leaving the Orexo AB (publ.) corporate website at orexo.com to visit the Orexo US, Inc. website at us.orexo.com.
